Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Abstract
BACKGROUND: Inherited mutations in the BRCA1 gene may be responsible for almost half of inherited breast carcinomas. However, somatic (acquired) mutations in BRCA1 have not been reported, despite frequent loss of heterozygosity (LOH or loss of one copy of the gene) at the BRCA1 locus and loss of BRCA1 protein in tumors. To address whether BRCA1 may be inactivated by pathways other than mutations in sporadic tumors, we analyzed the role of hypermethylation of the gene's promoter region. METHODS: Methylation patterns in the BRCA1 promoter were assessed in breast cancer cell lines, xenografts, and 215 primary breast and ovarian carcinomas by methylation-specific polymerase chain reaction (PCR). BRCA1 RNA expression was determined in cell lines and seven xenografts by reverse transcription-PCR. P values are two-sided. RESULTS: The BRCA1 promoter was found to be unmethylated in all normal tissues and cancer cell lines tested. However, BRCA1 promoter hypermethylation was present in two breast cancer xenografts, both of which had loss of the BRCA1 transcript. BRCA1 promoter hypermethylation was present in 11 (13%) of 84 unselected primary breast carcinomas. BRCA1 methylation was strikingly associated with the medullary (67% methylated; P =.0002 versus ductal) and mucinous (55% methylated; P =.0033 versus ductal) subtypes, which are overrepresented in BRCA1 families. In a second series of 66 ductal breast tumors informative for LOH, nine (20%) of 45 tumors with LOH had BRCA1 hypermethylation, while one (5%) of 21 without LOH was methylated (P =.15). In ovarian neoplasms, BRCA1 methylation was found only in tumors with LOH, four (31%) of 13 versus none of 18 without LOH (P =.02). The BRCA1 promoter was unmethylated in other tumor types. CONCLUSION: Silencing of the BRCA1 gene by promoter hypermethylation occurs in primary breast and ovarian carcinomas, especially in the presence of LOH and in specific histopathologic subgroups. These findings support a role for this tumor suppressor gene in sporadic breast and ovarian tumorigenesis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Changes in BRCA1 promoter status contribute to sporadic tumors.
“Given that changes in BRCA1 promoter status contribute to sporadic tumors [64,65], mutations outside the reading frame or changes in promoter methylation status could alter FANCJ expression and contribute to tumorigenesis.”
From Hereditary Breast Cancer and the BRCA1-Associated FANCJ/BACH1/BRIP1 (2011) · cites this paper as [65]
Mutations outside the reading frame or promoter methylation changes could alter FANCJ expression and contribute to tumorigenesis.
“Given that changes in BRCA1 promoter status contribute to sporadic tumors [64,65], mutations outside the reading frame or changes in promoter methylation status could alter FANCJ expression and contribute to tumorigenesis.”
From Hereditary Breast Cancer and the BRCA1-Associated FANCJ/BACH1/BRIP1 (2011) · cites this paper as [65]
Cites
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069 · see citing works
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,610 · see citing works
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J., Lee, M. K., Newman, B. M., Morrow, J. E., Anderson, L. A., Huey, B., & King, M. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,544 · see citing works
Cancer-epigenetics comes of age
Jones, P. A., & Laird, P. W. (1999) · Nature Genetics · doi:10.1038/5947 · Cited by 2,334 · see citing works
Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia
Baylln, S. B., Herman, J. G., Graff, J. R., Vertino, P. M., & Issa, J. J. (1997) · Advances in cancer research · doi:10.1016/s0065-230x(08)60702-2 · Cited by 1,913 · see citing works
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
Herman, J. G., Umar, A., Polyák, K., Graff, J. R., Ahuja, N., Issa, J. J., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., Kinzler, K. W., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6870 · Cited by 1,887 · see citing works
Kane, M., Loda, M. F., Gaida, G. M., Lipman, J., Mishra, R., Goldman, H., Jessup, J. M., & Kolodner, R. D. (1997) · PubMed · Cited by 1,476 · see citing works
Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., & Herman, J. G. (1999) · PubMed · Cited by 1,253 · see citing works
Self-citationFriedman, L. S., Ostermeyer, E. A., Szabo, C. I., Dowd, P., Lynch, E. D., Rowell, S. E., & King, M. (1994) · Nature Genetics · doi:10.1038/ng1294-399 · Cited by 622 · see citing works
Thompson, M. E., Jensen, R. A., Obermiller, P. S., Page, D. L., & Holt, J. T. (1995) · Nature Genetics · doi:10.1038/ng0495-444 · Cited by 584 · see citing works
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579 · see citing works
Esteller, M., Levine, R. L., Baylin, S. B., Ellenson, L. H., & Herman, J. G. (1998) · Oncogene · doi:10.1038/sj.onc.1202178 · Cited by 493 · see citing works
Self-citationThibodeau, S. N., French, A. J., Roche, P. C., Cunningham, J. M., Tester, D. J., Lindor, N. M., Möslein, G., Baker, S. M., Liskay, R. M., Burgart, L. J., et al. (1996) · PubMed · Cited by 466 · see citing works
Somatic mutations in the BRCA1 gene in sporadic ovarian tumours
Merajver, S., Pham, T. M., Caduff, R., Chen, M., Poy, E. L., Cooney, K., Weber, B., Collins, F., Johnston, C., & Frank, T. S. (1995) · Nature Genetics · doi:10.1038/ng0495-439 · Cited by 417 · see citing works
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas
Wilson, C., Ramos, L., Villaseñor, M. R., Anders, K. H., Press, M. F., Clarke, K., Karlan, B. Y., Chen, J.-J., Scully, R., Livingston, D. M., et al. (1999) · Nature Genetics · doi:10.1038/6029 · Cited by 414 · see citing works
Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer
Castilla, L. H., Couch, F. J., Erdos, M. R., Hoskins, K. F., Calzone, K., Garber, J. E., Boyd, J. A., Lubin, M. B., DeShano, M. L., Brody, L. C., et al. (1994) · Nature Genetics · doi:10.1038/ng1294-387 · Cited by 384 · see citing works
Methylation of the BRCA1 gene in sporadic breast cancer.
Dobrovic, A., & Simpfendorfer, D. (1997) · PubMed · Cited by 378 · see citing works
Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia.
Esteller, M., Corn, P. G., Ureña, J. M., Gabrielson, E. W., Baylin, S. B., & Herman, J. G. (1998) · PubMed · Cited by 356 · see citing works
Self-citationCatteau, A., Harris, W. H., Xu, C.-F., & Solomon, E. (1999) · Oncogene · doi:10.1038/sj.onc.1202509 · Cited by 354 · see citing works
Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma.
Knudson, A. G., Hethcote, H. W., & Brown, B. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.12.5116 · Cited by 351 · see citing works
Rice, J. C., Massey-Brown, K., & Futscher, B. W. (1998) · Oncogene · doi:10.1038/sj.onc.1202086 · Cited by 245 · see citing works
Futreal, P. A., Söderkvist, P., Marks, J. R., Iglehart, J. D., Cochran, C., Barrett, J. C., & Wiseman, R. W. (1992) · PubMed · Cited by 200 · see citing works
Mancini, D. N., Rodenhiser, D. I., Ainsworth, P., O’Malley, F. P., Singh, S. M., Xing, W., & Archer, T. (1998) · Oncogene · doi:10.1038/sj.onc.1201630 · Cited by 190 · see citing works
Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
Berchuck, A., Heron, K., Carney, M. E., Lancaster, J., Fraser, E. G., Vinson, V. L., Deffenbaugh, A. M., Miron, A., Marks, J. R., Futreal, P. A., et al. (1998) · PubMed · Cited by 169 · see citing works
Mutations at BRCA1: the medullary breast carcinoma revisited.
Eisinger, F., Jacquemier, J. D., Charpin, C., Stoppa‐Lyonnet, D., Paillerets, B. B., Peyrat, J., Longy, M., Guinebretière, J., Sauvan, R., Noguchi, T., et al. (1998) · PubMed · Cited by 162 · see citing works
Allele loss from chromosome 17 in ovarian cancer.
Russell, S. E. H., Hickey, G. I., Lowry, W. S., White, P., & Atkinson, R. (1990) · PubMed · Cited by 156 · see citing works
Magdinier, F., Ribieras, S., Lenoir, G., Frappart, L., & Dante, R. (1998) · Oncogene · doi:10.1038/sj.onc.1202248 · Cited by 134 · see citing works
Oto, M., Miyaké, S., & Yuasa, Y. (1993) · Analytical Biochemistry · doi:10.1006/abio.1993.1379 · Cited by 122 · see citing works
Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.
Phillips, K., Nichol, K., Ozçelik, H., Knight, J., Done, S., Goodwin, P., & Andrulis, I. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.5.469 · Cited by 111 · see citing works
Distinct transcription start sites generate two forms of BRCA1 mRNA
Xu, C., Brown, M. A., Chambers, J. A., Griffiths, B. L., Nicolai, H., & Solomon, E. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.12.2259 · Cited by 107 · see citing works
Breast cancer genes—what are the real risks?
Easton, D. F. (1997) · Nature Genetics · doi:10.1038/ng0797-210 · Cited by 96 · see citing works
p53 Mutation as a Genetic Trait of Typical Medullary Breast Carcinoma
de Crémoux, P., Vincent‐Salomon, A., Liva, S., Dendale, R., Bouchindhomme, B., Martin, E., Sastre‐Garau, X., Magdelénat, H., Fourquet, A., & Soussi, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.641 · Cited by 82 · see citing works
Loss of heterozygosity in the region including the BRCA1 gene on 17q in colon cancer.
García-Patiño, E., Gomendio, B., Lleonart, M., Silva, J., García, J., Provencio, M., Cubedo, R., España, P., Cajal, S. Y., & Bonilla, F. (1998) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(97)00460-3 · Cited by 47 · see citing works
A candidate tumor suppressor gene in human breast cancers.
Schott, D. R., Chang, J. N., Deng, G., Kurisu, W., Kuo, W., Gray, J. W., & Smith, H. S. (1994) · PubMed · Cited by 44 · see citing works
Growth and metastasis of surgical specimens of human breast carcinomas in SCID mice.
Sakakibara, T., Xu, Y., Bumpers, H. L., Chen, F. A., Bankert, R. B., Arredondo, M. A., Edge, S. B., & Repasky, E. A. (1996) · PubMed · Cited by 42 · see citing works
Loss of heterozygosity in BRCA1 and BRCA2 markers and high‐grade malignancy in breast cancer
Silva, J. M., Gonzalez, R. M., Provencio, M., Dominguez, G., Garcia, J. M., Gallego, I., Palacios, J., España, P., & Bonilla, F. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006082117266 · Cited by 38 · see citing works
Böhm, M., Kirch, H., Otto, T., Rubben, H., & Wieland, I. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970620)74:3 · Cited by 34 · see citing works
Fuchs, J., Wenderoth, M., von Schweinitz, D., Haindl, J., & Leuschner, I. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981201)83:11 · Cited by 23 · see citing works
p53 involvement in BRCA1-associated breast cancer
Eisinger, F., Jacquemier, J. D., Guinebretière, J., Bimbaum, D., & Sobol, H. (1997) · The Lancet · doi:10.1016/s0140-6736(05)70461-x · Cited by 17 · see citing works
Flagged first, then by citations
2 of the 41 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · see citing works
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927 · see citing works
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,719 · see citing works
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648 · see citing works
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,681 · see citing works
Self-citationPan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064 · see citing works
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O. A., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,164 · see citing works
A gene hypermethylation profile of human cancer.
Esteller, M., Corn, P. G., Baylin, S. B., & Herman, J. G. (2001) · PubMed · Cited by 2,032 · see citing works
Self-citationGene-expression profiles in hereditary breast cancer.
Hedenfalk, I., Duggan, D., Chen, Y.-D., Radmacher, M., Bittner, M., Simon, R., Meltzer, P., Gusterson, B., Esteller, M., Raffeld, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440801 · Cited by 978 · see citing works
Self-citationHallmarks of 'BRCAness' in sporadic cancers
Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,651 · see citing works
DNA hypermethylation in tumorigenesis: epigenetics joins genetics
Baylin, S. B., & Herman, J. G. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(99)01971-x · Cited by 1,615 · see citing works
Deconstructing the molecular portraits of breast cancer
Prat, A., & Perou, C. M. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.11.003 · Cited by 1,345 · see citing works
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Knijnenburg, T., Wang, L., Zimmermann, M. T., Chambwe, N., Gao, G. F., Cherniack, A. D., Fan, H., Shen, H., Way, G. P., Greene, C. S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.076 · Cited by 1,126 · see citing works
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051 · see citing works
Fong, P. C. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui‐Roelvink, M., Gourley, C., Grève, J. D., Lubiński, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,009 · see citing works
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967 · see citing works
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
Foulkes, W. D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg050 · Cited by 970 · see citing works
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A. N. J., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazińska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 909 · see citing works
Triple negative tumours: a critical review
Reis-Filho, J. S., & Tutt, A. N. J. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02889.x · Cited by 883 · see citing works
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945 · see citing works
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817 · see citing works
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R. A., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798 · see citing works
DNA methylation profiling in the clinic: applications and challenges
Heyn, H., & Esteller, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3270 · Cited by 747 · see citing works
Self-citationCancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours
Esteller, M., & Herman, J. G. (2001) · The Journal of Pathology · doi:10.1002/path.1024 · Cited by 743 · see citing works
Self-citationBadve, S., Dabbs, D. J., Schnitt, S. J., Baehner, F. L., Decker, T. W., Eusebi, V., Fox, S. B., Ichihara, S., Jacquemier, J. D., Lakhani, S. R., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.200 · Cited by 686 · see citing works
Wright, M. H., Calcagno, A. M., Salcido, C. D., Carlson, M. D., Ambudkar, S. V., & Varticovski, L. (2008) · Breast Cancer Research · doi:10.1186/bcr1855 · Cited by 643 · see citing works
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O’Carrigan, B., Jackson, S. P., & Yap, T. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 623 · see citing works
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres‐Lockhart, K., Prat, A., Antón, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 609 · see citing works
Prat, J. (2012) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-012-1203-5 · Cited by 600 · see citing works
BRCA1 dysfunction in sporadic basal-like breast cancer
Turner, N. C., Reis-Filho, J. S., Russell, A. M., Springall, R. J., Ryder, K., Steele, D., Savage, K., Gillett, C. E., Schmitt, F. C., Ashworth, A., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1210014 · Cited by 574 · see citing works
Polak, P., Kim, J., Braunstein, L. Z., Karlic, R., Haradhavala, N. J., Tiao, G., Rosebrock, D., Livitz, D., Kübler, K., Mouw, K. W., et al. (2017) · Nature Genetics · doi:10.1038/ng.3934 · Cited by 531 · see citing works
ABERRANT DNA METHYLATION AS A CANCER-INDUCING MECHANISM
Esteller, M. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095832 · Cited by 549 · see citing works
Self-citationThe DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy
Goldstein, M., & Kastan, M. B. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-081313-121208 · Cited by 590 · see citing works
Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors
Taniguchi, T., Tischkowitz, M. D., Ameziane, N., Hodgson, S. V., Mathew, C. G., Joenje, H., Mok, S. C., & D’Andrea, A. D. (2003) · Nature Medicine · doi:10.1038/nm852 · Cited by 537 · see citing works
Hon, G. C., Hawkins, R. D., Caballero, O. L., Lo, C., Lister, R., Pelizzola, M., Valsesia, A., Ye, Z., Kuan, S., Edsall, L. E., et al. (2012) · Genome Research · doi:10.1101/gr.125872.111 · Cited by 583 · see citing works
DNA Methyltransferases, DNA Damage Repair, and Cancer
Jin, B., & Robertson, K. D. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-9967-2_1 · Cited by 521 · see citing works
Signatures of copy number alterations in human cancer
Steele, C. D., Abbasi, A., Islam, S. M. A., Bowes, A. L., Khandekar, A., Haase, K., Hames-Fathi, S., Ajayi, D., Verfaillie, A., Dhami, P., et al. (2022) · Nature · doi:10.1038/s41586-022-04738-6 · Cited by 487 · see citing works
Valinluck, V., & Sowers, L. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3123 · Cited by 502 · see citing works
Early Events in the Pathogenesis of Epithelial Ovarian Cancer
Landen, C. N., Birrer, M. J., & Sood, A. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9970 · Cited by 462 · see citing works
Miller, R. E., Leary, A. F., Scott, C. L., Serra, V., Lord, C. J., Bowtell, D. D. L., Chang, D. K.-F., Garsed, D. W., Jonkers, J., Ledermann, J. A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2102 · Cited by 483 · see citing works
Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N. J., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 480 · see citing works
Epigenetics and human disease: translating basic biology into clinical applications
Rodenhiser, D. I. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.050774 · Cited by 474 · see citing works
Tan, D. S., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S., Ardern-jones, A., Norman, A., Kaye, S., & Gore, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1703 · Cited by 489 · see citing works
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
Metzger, O., Tutt, A. N. J., de Azambuja, E., Saini, K. S., Viale, G., Loi, S., Bradbury, I., Bliss, J. M., Azim, H. A., Ellis, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2010 · Cited by 464 · see citing works
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
Costa, R. L. B., Han, H. S., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4697-y · Cited by 439 · see citing works
Costello, J., & Plass, C. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.5.285 · Cited by 447 · see citing works
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis
Esteller, M. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.26.3001 · Cited by 441 · see citing works
Self-citationTriple-Negative Breast Cancer: Risk Factors to Potential Targets
Schneider, B. P., Winer, E. P., Foulkes, W. D., Garber, J. E., Perou, C. M., Richardson, A. L., Sledge, G. W., & Carey, L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1208 · Cited by 437 · see citing works
miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors
Moskwa, P., Buffa, F. M., Pan, Y., Panchakshari, R. A., Gottipati, P., Muschel, R. J., Beech, J. S., Kulshrestha, R., Abdelmohsen, K., Weinstock, D. M., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.12.005 · Cited by 428 · see citing works
DNA methylation and the regulation of gene transcription
Attwood, J. T., Yung, R. L., & Richardson, B. C. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-002-8420-z · Cited by 426 · see citing works
Metabolic control of epigenetics in cancer
Kinnaird, A. S., Zhao, S., Wellen, K. E., & Michelakis, E. D. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.82 · Cited by 419 · see citing works
The cancer epigenome—components and functional correlatesPreprint
Ting, A. H., McGarvey, K. M., & Baylin, S. B. (2006) · Genes & Development · doi:10.1101/gad.1464906 · Cited by 416 · see citing works
The p53 pathway in breast cancer
Gasco, M., Shami, S. K., & Crook, T. (2002) · Breast Cancer Research · doi:10.1186/bcr426 · Cited by 393 · see citing works
The role of enhancers in cancer
Sur, I., & Taipale, J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.62 · Cited by 382 · see citing works
Xu, J., Chen, Y., & Olopade, O. I. (2010) · Genes & Cancer · doi:10.1177/1947601910378691 · Cited by 384 · see citing works
Age-associated DNA methylation in pediatric populationsPreprint
Alisch, R. S., Barwick, B. G., Chopra, P., Myrick, L. K., Satten, G. A., Conneely, K. N., & Warren, S. T. (2012) · Genome Research · doi:10.1101/gr.125187.111 · Cited by 380 · see citing works
Triple-negative breast cancer: treatment challenges and solutions
Jérusalem, G., Collignon, J., Schroeder, H., & Lousberg, L. (2016) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s69488 · Cited by 393 · see citing works
“Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
Davis, A., Tinker, A. V., & Friedlander, M. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.038 · Cited by 433 · see citing works
The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication
Tarsounas, M., & Sung, P. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0218-z · Cited by 366 · see citing works
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 356 · see citing works
CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter
Choudhury, S. R., Cui, Y., Lubecka, K., Stefañska, B., & Irudayaraj, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10234 · Cited by 352 · see citing works
Lok, B. H., Gardner, E. E., Schneeberger, V. E., Ni, A., Desmeules, P., Rekhtman, N., de Stanchina, E., Teicher, B. A., Riaz, N., Powell, S. N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1040 · Cited by 350 · see citing works
Relevance of DNA methylation in the management of cancer
Esteller, M. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01115-x · Cited by 329 · see citing works
Self-citationBRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin, R. L., Nemeth, E., Tran, H., Shvartsman, H. S., Cass, I. A., Narod, S. A., & Karlan, B. Y. (2000) · PubMed · Cited by 328 · see citing works
DNA Methylation: An Alternative Pathway to Cancer
Wajed, S., Laird, P. W., & DeMeester, T. R. (2001) · Annals of Surgery · doi:10.1097/00000658-200107000-00003 · Cited by 328 · see citing works
Watkins, J. A., Irshad, S., Grigoriadis, A., & Tutt, A. N. (2014) · Breast Cancer Research · doi:10.1186/bcr3670 · Cited by 327 · see citing works
The role of PARP in DNA repair and its therapeutic exploitation
Javle, M. M., & Curtin, N. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.382 · Cited by 320 · see citing works
New insights into ovarian cancer pathology
Prat, J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds300 · Cited by 319 · see citing works
Characteristics of triple-negative breast cancer
de Ruijter, T. C., Veeck, J., de Hoon, J. P. J., van Engeland, M., & Tjan‐Heijnen, V. C. G. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0957-x · Cited by 315 · see citing works
Targeting epigenetic regulators to overcome drug resistance in cancers
Wang, N., Ma, T., & Yu, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01341-7 · Cited by 319 · see citing works
The DNA methylation landscape in cancer
Skvortsova, K., Stirzaker, C., & Taberlay, P. C. (2019) · Essays in Biochemistry · doi:10.1042/ebc20190037 · Cited by 312 · see citing works
Cancer Stem Cells Contribute to Cisplatin Resistance in Brca1/p53 –Mediated Mouse Mammary Tumors
Shafee, N., Smith, C. R., Wei, S., Kim, Y. H., Mills, G. B., Hortobágyi, G. N., Stanbridge, E. J., & Lee, E. Y.-H. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5480 · Cited by 305 · see citing works
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
Tarón, M., Rosell, R., Felip, E., Méndez, P., Souglakos, J., Ronco, M. S., Queralt, C., Majo, J., Sánchez, J. M., Sánchez, J. J., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh260 · Cited by 308 · see citing works
BRCA1 Mutation Analysis of 41 Human Breast Cancer Cell Lines Reveals Three New Deleterious Mutants
Elstrodt, F., Hollestelle, A., Nagel, J. H. A., Gorin, M. A., Wasielewski, M., van den Ouweland, A., Merajver, S. D., Ethier, S. P., & Schutte, M. E. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2853 · Cited by 306 · see citing works
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines
Hollestelle, A., Nagel, J. H. A., Smid, M., Lam, S., Elstrodt, F., Wasielewski, M., Ng, S. S., French, P. J., Peeters, J. K., Rozendaal, M. J., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0460-8 · Cited by 296 · see citing works
The epigenetics of breast cancer
Jovanovic, J., Rønneberg, J. A., Tost, J., & Kristensen, V. N. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.002 · Cited by 300 · see citing works
Kondrashova, O., Topp, M. D., Nesic, K., Lieschke, E., Ho, G., Harrell, M. I., Zapparoli, G. V., Hadley, A., Hollian, R., Boehm, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05564-z · Cited by 302 · see citing works
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
Maxwell, K. N., Wubbenhorst, B., Wenz, B. M., De Sloover, D., Pluta, J., Emery, L., Barrett, A., Kraya, A. A., Anastopoulos, I. N., Yu, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00388-9 · Cited by 296 · see citing works
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Press, J. Z., Luca, A. D., Boyd, N., Young, S. S., Troussard, A. A., Ridge, Y., Kaurah, P., Kalloger, S. E., Blood, K. A., Smith, M. J., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-17 · Cited by 287 · see citing works
DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes
Kennedy, R. D., & D’Andrea, A. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4171 · Cited by 283 · see citing works
Bosch, A., Eroles, P., Zaragozá, R., Vinã, J. R., & Lluch, A. M. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.12.002 · Cited by 281 · see citing works
DNA Methylation Profiling: An Emerging Paradigm for Cancer Diagnosis
Papanicolau‐Sengos, A., & Aldape, K. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042220-022304 · Cited by 283 · see citing works
Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers
Jazaeri, A. A., Yee, C. J., Sotiriou, C. P., Brantley, K., Boyd, J. A., & Liu, E. T. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.13.990 · Cited by 282 · see citing works
de Cáceres, I. I., Battagli, C., Esteller, M., Herman, J. G., Dulaimi, E., Edelson, M. I., Bergman, C. A., Ehya, H., Eisenberg, B. L., & Cairns, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1529 · Cited by 280 · see citing works
Self-citationDammann, R., Yang, G., & Pfeifer, G. P. (2001) · PubMed · Cited by 281 · see citing works
Prat, J., D′Angelo, E., & Espinosa, Í. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.06.018 · Cited by 277 · see citing works
DNA Damage Response Genes and the Development of Cancer Metastasis
Broustas, C. G., & Lieberman, H. B. (2014) · Radiation Research · doi:10.1667/rr13515.1 · Cited by 276 · see citing works
Rosen, E. M., Fan, S., Pestell, R. G., & Goldberg, I. D. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10257 · Cited by 268 · see citing works
Triple negative breast cancers: Clinical and prognostic implications
Dawson, S., Provenzano, E., & Caldas, C. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70013-9 · Cited by 266 · see citing works
The Role of DNA Methylation in Cancer
Lakshminarasimhan, R., & Liang, G. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43624-1_7 · Cited by 267 · see citing works
Garcia, A. I., Buisson, M., Bertrand, P., Rimokh, R., Rouleau, É., López, B. S., Lidereau, R., Mikaélian, I., & Mazoyer, S. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100136 · Cited by 265 · see citing works
Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer
Agrelo, R., Cheng, W.-H., Setien, F., Ropero, S., Espada, J., Fraga, M. F., Herranz, M., Paz, M. F., Sanchez-Cespedes, M., Artiga, M. J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600645103 · Cited by 264 · see citing works
Self-citationShames, D. S., Girard, L., Gao, B., Sato, M., Lewis, C. M., Shivapurkar, N., Jiang, A., Perou, C. M., Kim, Y. H., Pollack, J. R., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030486 · Cited by 262 · see citing works
Drew, Y., Mulligan, E. A., Vong, W., Thomas, H. D., Kahn, S., Kyle, S., Mukhopadhyay, A., Los, G., Hostomský, Z., Plummer, E. R., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq509 · Cited by 262 · see citing works
The role of DNA methylation in cancer development.
Łuczak, M. W., & Jagodziński, P. P. (2006) · PubMed · doi:10.5603/4561 · Cited by 260 · see citing works
Epigenetic lesions causing genetic lesions in human cancer
Esteller, M. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00303-8 · Cited by 259 · see citing works
Self-citationOsborne, C., Wilson, P., & Tripathy, D. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-361 · Cited by 257 · see citing works
Targeting Epigenetics in Cancer
Bennett, R. L., & Licht, J. D. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-105106 · Cited by 252 · see citing works
The Science behind Microgreens as an Exciting New Food for the 21st Century
Choe, U., Yu, L. L., & Wang, T. T. Y. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b03096 · Cited by 277 · see citing works
Virmani, A. K., Rathi, A., Sathyanarayana, U. G., Padar, A., Huang, C., Cunnigham, H. T., Farinas, A. J., Milchgrub, S., Euhus, D., Gilcrease, M. Z., et al. (2001) · PubMed · Cited by 247 · see citing works
- Authors
- Esteller, M.
- Affiliations
- Roswell Park Comprehensive Cancer Center (US)
- Corresponding author
- Esteller, M.
- ORCID
- Esteller, M.
- Venue
- Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-04-05
- Volume
- 92
- Issue
- 7
- Pages
- 564-569
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2160234594
- Cited by
- 1,233
- References
- 41
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 37 · 2023: 46 · 2022: 49 · 2021: 40 · 2020: 53 · 2019: 43 · 2018: 60 · 2017: 48 · 2016: 52 · 2015: 69 · 2014: 56 · 2013: 57 · 2012: 69
- FWCI
- 22.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Funders
- National Cancer Institute (R01CA043318, CA 43318)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Keywords
- BRCA1 promoter hypermethylation, sporadic breast cancer, ovarian cancer, loss of heterozygosity, gene silencing, tumor suppressor, medullary breast carcinoma, mucinous breast carcinoma, histological subtypes, epigenetic silencing, breast cancer xenografts
- MeSH terms
- Breast Neoplasms, Female, Humans, Methylation, Ovarian Neoplasms, Promoter Regions, Genetic, RNA, RNA, Neoplasm, Transplantation, Heterologous, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Carcinoma, Ductal, Breast, Genes, BRCA1, Loss of Heterozygosity, Reverse Transcriptase Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
